Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 34.50
- Piotroski Score 1.00
- Grade Buy
- Symbol (AVXL)
- Company Anavex Life Sciences Corp.
- Price $8.50
- Changes Percentage (-4.37%)
- Change -$0.39
- Day Low $8.42
- Day High $9.24
- Year High $10.45
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $11.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.50
- Trailing P/E Ratio -7.74
- Forward P/E Ratio -7.74
- P/E Growth -7.74
- Net Income $-47,505,000
Income Statement
Quarterly
Annual
Latest News of AVXL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
Anavex's CEO discussed plans to focus on EMA submission, address concerns about patient data variations, clarify stock offering intentions, explain dose dependency in Alzheimer's data, and mentioned c...
By Yahoo! Finance | 1 month ago -
Institutions own 38% of Anavex Life Sciences Corp. (NASDAQ:AVXL) shares but individual investors control 59% of the company
Individual investors have significant control over Anavex Life Sciences, holding 59% ownership, giving them power to influence management decisions. Institutional investors make up 38%, with no domina...
By Yahoo! Finance | 4 months ago
